entertainment -WSS

entertainment

author：leisure time 2025-09-27 12:48:00 - browse：819

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Free medical tuition alone isn't enough to close gaps in primary care

WSS

Oak Street deal isn't the answer to health care's woes

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

STAT series 'Denied by AI' wins major journalism prizes

A virus, fished out of a lake, may have saved a man’s life

Why Charlie Gard's case is so disturbing to Americans

Oak Street deal isn't the answer to health care's woes

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Galapagos to make CAR

Guidelines to prevent youth baseball injuries need more muscle

Abbott's new stent may help patients with peripheral artery disease

In Memoriam: Notable people who died in 2023

AI can decode, harness the power of the humane immune system

The cancer drug shortage isn’t new — and neither are the solutions

The United States must get value

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A Q&A with the global head of Boehringer Ingelheim's innovation unit

explore

Obesity drug from Roche shows promise in early study

Phenylephrine and the overlooked value of the placebo effect

Lilly’s weekly insulin works as well as daily products, new studies show

The United States must get value

FDA panel signals lack of confidence in Amgen cancer drug data

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

focus

Wikipedia

focus

leisure time